Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Emisphere -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (214)	5/8/2003 6:51:23 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 272

<<The formulation uses Emisphere's eligen(TM) oral drug delivery technology to deliver the insulin in a capsule.>> and <<Previous studies with an unformulated oral insulin capsule showed peak plasma insulin concentrations within 20-25 minutes.>> So, how many formulation they need to test before doing it right? Didn't they try to combine tablet formulation in capsule? Who will know what are bios doing this days? Not me! Miljenko